



**HAL**  
open science

## Could the use of saliva substitutes improve food oral processing in individuals with xerostomia? A systematic review

Sophie Piaton, Anne Duconseille, Valérie Roger-leroi, Martine Hennequin

### ► To cite this version:

Sophie Piaton, Anne Duconseille, Valérie Roger-leroi, Martine Hennequin. Could the use of saliva substitutes improve food oral processing in individuals with xerostomia? A systematic review. *Journal of Texture Studies*, 2021, 52 (3), pp.278-293. 10.1111/jtxs.12591 . hal-03285510

**HAL Id: hal-03285510**

**<https://uca.hal.science/hal-03285510>**

Submitted on 13 Jul 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

1 **Could the use of saliva substitutes improve food oral processing in individuals with**  
2 **xerostomia? A systematic review**

3

4 **Short title : Saliva substitutes and FOP**

5

6 Sophie Piaton<sup>1,2</sup>, Anne Duconseille<sup>1</sup>, Valérie Roger-Leroi<sup>1,2</sup>, Martine Hennequin<sup>1,2</sup>

7

8 <sup>1</sup> Université Clermont Auvergne, CROC, F-63000 Clermont-Ferrand, France.

9 <sup>2</sup> CHU de Clermont-Ferrand, Service d'Odontologie, F-63003 Clermont-Ferrand, France

10

11 **Corresponding author**

12 Prof Martine Hennequin

13 CROC EA4847 UFR d'Odontologie

14 2 rue de Braga

15 63000 Clermont-Ferrand

16 France

17 Email: [martine.hennequin@uca.fr](mailto:martine.hennequin@uca.fr)

18 Tel: 00 33 4 73 17 73 81

19

20

21

22

23 **ABSTRACT**

24 Xerostomia **was is** associated with food avoidance and low nutritional assessment. This review  
25 seeks to document whether products called “saliva substitutes” or “artificial saliva” can really  
26 replace saliva in food oral processing. Pubmed and Science Direct were searched for articles  
27 using the keywords “saliva substitutes” and “artificial saliva”. An advanced search was applied  
28 using the terms “xerostomia” and/or “food oral processing” and/or “eating” and/or  
29 “mastication” and/or “chewing” and/or “swallowing”. The analysis methods and the inclusion  
30 criteria were documented in a protocol published in the International prospective register of  
31 systematic reviews (PROSPERO with the registration number CRD42019124585).  
32 The search included 43 articles, published between 1979 and 2017. Among the included studies,  
33 17 were observational studies, 5 were pilot studies, 21 were crossover studies and 14 of these  
34 studies were blinded. The Strobe score for the included articles varied from 7.5 to 20.  
35 The possible effects of the use of saliva substitutes on the ingestion function were poorly  
36 investigated. No evidence was based on physiological studies. It is unknown whether using a  
37 saliva substitute has an effect on the composition and rheological properties of the food bolus,  
38 on the lubrication of the oral and laryngeal mucosa or on both phenomena. Moreover, saliva  
39 substitutes were not formulated to improve food oral processing and most of them are flavoured.  
40 New saliva substitutes and artificial saliva should be designed and formulated to improve food  
41 oral processing.

42  
43 **Keywords:** Xerostomia, **Sjögren’s syndrome**, saliva substitutes, artificial saliva, Food oral  
44 Processing, review

45  
46  
47

## 48 1 INTRODUCTION

49 Xerostomia is a subjective feeling of dryness in the mouth related to possible quantitative and  
50 qualitative changes in saliva composition (Fox, Busch, & Baum, 1987). It should be  
51 differentiated from hyposalivation which results from an objective assessment of a reduced  
52 salivary flow rate (Łysik, Niemirowicz-Laskowska, Bucki, Tokajuk, & Mystkowska, 2019).  
53 The causes of xerostomia are heterogenous, and may or may not be related to saliva production  
54 deficiencies. Among the origins of xerostomia, one can distinguish the consequences of salivary  
55 diseases (salivary gland trauma, ~~and~~ tumor, surgery or radiotherapies), from the effects of  
56 systemic chronic diseases (~~chronic, autoimmune,~~ diabete mellitus, Sjogren's syndrome, lupus  
57 erythematosus and others autoimmune disorders), dehydration, mouth breathing or the adverse  
58 effects of drugs. More than 400 medicines are associated with xerostomia (Porter, Scully, &  
59 Hegarty, 2004). Determining the epidemiology of xerostomia is complex due to the unclear  
60 definitions of dry mouth being used and the different methods for measuring this condition  
61 (Ying Joanna & Thomson, 2015). A systematic review reported that the prevalence of  
62 xerostomia ranged from 8% to 42%, while the prevalence of hyposyalia varied from 12% to  
63 47% (Hopcraft & Tan, 2010). Xerostomia prevalence is estimated to be approximately 20% in  
64 the general population, with an increased prevalence in women (up to 30%) and in elderlies (up  
65 to 50%) (Furness, Worthington, Bryan, Birchenough, & McMillan, 2011). Overall, 54% of  
66 people complaining of xerostomia actually had objective evidence of hyposalivation after  
67 salivary flow measurements were taken (Longman et al., 1997).

68 Various treatments were proposed to patients with xerostomia. Saliva stimulants and saliva  
69 substitutes aim to alleviate the symptoms of xerostomia. Saliva stimulants activate the salivary  
70 gland function. Their composition is based either on pilocarpine, a nonselective muscarinic  
71 agonist, or on cemivaline, which has specific affinity for receptor subtypes. The indications of  
72 saliva stimulants are restricted to individuals suffering from hyposalivation. Saliva substitutes

73 have no effect on saliva production. They are indicated for all patients suffering from  
74 xerostomia, including those having hyposalivation. Artificial saliva products definitely are not  
75 saliva. They were developed to imitate and act as saliva but they do not act as saliva for all of  
76 its complex functions (antimicrobial, digestive/perceptive, teeth protection etc..). ~~are indicated~~  
77 ~~for all patients suffering for xerostomia, including those having hyposalivation.~~

78 The effects of saliva substitutes have been reported in many studies measuring self-perception  
79 of pain, comfort in mouth and quality of life related to oral health. However, it is not clear  
80 whether saliva substitutes could improve eating capacities and the nutritional status. The  
81 question is challenging, as saliva plays vital roles in maintaining oral health and in food oral  
82 processing (FOP). Food oral processing covers all ingestive functions and includes sucking,  
83 biting, chewing, manipulating the food with the tongue and swallowing. The dryness of the  
84 mouth affects both the oral preparatory and oral phases of swallowing, and can lead to impaired  
85 bolus formation and oropharyngeal bolus transport. This can cause chewing and swallowing  
86 difficulty and may influence the quality and/or quantity of dietary intakes.

87 Previous research showed that a reduced salivary flow rate and/or subjective oral dryness were  
88 associated with food avoidance and low nutritional assessment. It was shown that the use of a  
89 mucin-containing saliva substitute three times a day before meals treats xerostomia and oral  
90 mucosa disorder in elderlies (Blixt-Johansen, Sjöholm, Wiesel, & Ek, 1992). Moreover, meals  
91 duration was longer after the treatment period than before. The consequences of xerostomia on  
92 swallowing depend on the food type. For friable and non hydrophilic foods, the collection of  
93 particles into a single bolus could be affected, as could its transportation towards the pharynx  
94 (Liedberg, Ekberg, & Owall, 1991). Indeed, there is little information about the association  
95 between hyposalivation and actual nutrient intake (Iwasaki et al., 2016). A systematic review  
96 and meta-analysis identified a clear gap in knowledge on the influence of saliva incorporation  
97 and oral lubrication on appetite ratings and food intake (Krop et al., 2018). The influence of the

98 lubrication parameters of food on appetite and food intake remains largely unquantified. This  
99 review seeks to document whether the products called “saliva substitutes” or “artificial saliva”  
100 can really replace saliva during food oral processing.

## 101 **2 MATERIALS AND METHODS**

102 A systematic review was conducted based on the Preferred Reporting Items for Systematic  
103 reviews and Meta-analyses Protocol (PRISMA-P) statement (Moher et al., 2015). The analysis  
104 methods and inclusion criteria were documented in a protocol published in the International  
105 prospective register of systematic reviews (PROSPERO with the registration number  
106 CRD42019124585).

### 107 **2.1 Search**

108 The search was designed to find articles reporting the use of saliva substitutes in individuals  
109 with xerostomia, in order to answer the question: Could the use of saliva substitutes improve  
110 food oral processing?

### 111 **2.2 Information sources**

112 Pubmed and Science Direct were searched for articles using the keywords “saliva substitutes”  
113 and “artificial saliva”. An advanced search was applied using the terms “xerostomia” and/or  
114 “food oral processing” and/or “eating” and/or “mastication” and/or “chewing” and/or  
115 “swallowing”. The PRISMA protocol was applied for article selection reviews (Moher et al.,  
116 2015). Criteria for exclusion were: articles not written in English, animal studies, in vitro  
117 studies, articles with off-topics and reviewed articles. The remaining records were assessed for  
118 screening and abstracts were read. Any article reporting an evaluation of saliva substitute was  
119 included in the eligibility phase. The remaining records were assessed for eligibility and full  
120 texts were read. The Strobe Grade approach (Cuschieri, 2019) was used to grade the quality of  
121 the evidence in the different studies. Three systematic reviews aimed at evaluating the efficacy

122 of interventions for management of dry mouth were excluded (Furness, Bryan, McMillan,  
123 Birchenough, & Worthington, 2013; Furness et al., 2011; Hahnel, Behr, Handel, & Bürgers,  
124 2009).

### 125 **2.3 Data extraction**

126 A Microsoft Excel® chart file was created and a pre-piloted form was tested for 10 articles by  
127 two investigators. Any quantitative or qualitative variable was considered as one item and noted  
128 as a column label while the articles included were listed in the rows. Depending on the  
129 articles, some items were either not described or not available. Finally, twenty eight items were  
130 listed for data extraction: design trial; population description (number of subjects, number of  
131 females, number of males, age, number of groups of individuals, number of treatment per  
132 groups, aetiology of xerostomia, exclusion criteria, salivary flow); treatment (saliva substitute  
133 name, form, composition, posology); study parameters (duration, measurement frequency,  
134 control group, placebo, primary outcomes, secondary outcomes); objective and/or subjective  
135 measurements; significant results for primary and secondary outcomes; subjects' preferences  
136 for using a substitute; study grade. A last column was added to check whether saliva substitutes  
137 had an effect on one or more FOP functions such as biting, chewing, manipulating food between  
138 tongue, palate, teeth and cheek and /or swallowing.

### 139 **2.4 Strategy for data synthesis**

140 Qualitative results were written as a narrative review. The term “saliva substitute” was used to  
141 refer to both “saliva substitute” and “artificial saliva”.

142

143

144

145 **3 RESULTS**

146 **3.1 Search results**

147 **The flow chart for inclusions is presented in Figure 1.** The search included 43 articles, published  
148 between 1979 and 2017 (Aliko, Alushi, Tafaj, & Isufi, 2012; Alpöz et al., 2015, 2008; Alves,  
149 Motta, Messina, & Migliari, 2004; Andersson et al., 1995; Apperley, Medicott, Rich, Hanning,  
150 & Huckabee, 2017; Blixt-Johansen et al., 1992; Bots et al., 2005; Dalodom et al., 2016; Davies  
151 & Singer, 1994; Dirix, Nuyts, Vander Poorten, Delaere, & Van den Bogaert, 2007; Donath,  
152 Tonner, Chavda, Gatignol, & Bouyrie, 2016; Duxbury, Thakker, & Wastell, 1989; Epstein,  
153 Emerton, Le, & Stevenson-Moore, 1999; Epstein & Stevenson-Moore, 1992; Frost, Shirlaw,  
154 Walter, & Challacombe, 2002; Furumoto, Barker, Carter-Hanson, & Barker, 1998; Gil-  
155 Montoya, Subirá, Ramón, & González-Moles, 2008; Heydarirad, Rezaeizadeh, Choopani,  
156 Mosavat, & Ameri, 2017; Jellema et al., 2001; Johansson, Andersson, Attström, Glantz, &  
157 Larsson, 1994; Klestov et al., 1981; Matear & Barbaro, 2005; McMillan, Tsang, Wong, & Kam,  
158 2006; Momm, Volegova-Neher, Schulte-Mönting, & Guttenberger, 2005; Morales-Bozo et al.,  
159 2017; Mouly, Orlor, et al., 2007; Mouly, Salom, et al., 2007; Nakamoto, 1979; Oh, Lee, Kim,  
160 & Kho, 2008; Regelink, Vissink, Reintsema, & Nauta, 1998; Rogus-Pulia, Gangnon, Kind,  
161 Connor, & Asthana, 2018; Salom et al., 2015; Shahdad, Taylor, Barclay, Steen, & Preshaw,  
162 2005; Silvestre, Minguez, & Suñe-Negre, 2009; Skrinjar et al., 2015; Stewart et al., 1998;  
163 Sweeney, Bagg, Baxter, & Aitchison, 1997; Temmel, Quint, Schickinger-Fischer, & Hummel,  
164 2005; van der Reijden, van der Kwaak, Vissink, Veerman, & Amerongen, 1996; Visch,  
165 Gravenmade, Schaub, Van Putten, & Vissink, 1986; Vissink et al., 1983)

166 Among the included studies, 17 were observational studies, 5 were pilot studies, 21 were cross-  
167 over studies and 14 of these studies were blinded. The Strobe score for the included articles  
168 varied from 7.5 to 20. **Xerostomia aetiologies and methods used to assess Food Oral Processing**  
169 **in included studies are reported in Table 1.**



170 **3.2 Review**

171 There are few objective and direct evaluations of the impact of the use of saliva substitutes on  
172 Food Oral Processing. Overall, 30 studies used visual analogue scales and /or Likert scales to  
173 evaluate the self-perception of subjects for the level of dryness of their mouth or throat,  
174 swallowing, chewing and speaking difficulties, level of thirst, taste disturbance, or denture  
175 retention (Aliko et al., 2012; Alpöz et al., 2015, 2008; Dalodom et al., 2016; Davies, Daniels,  
176 Pugh, & Sharma, 1998; Davies & Singer, 1994; Dirix et al., 2007; Donath et al., 2016; Epstein  
177 et al., 1999; Frost et al., 2002; Johansson et al., 1994; Matear & Barbaro, 2005; Nakamoto,  
178 1979; Regelin et al., 1998; Temmel et al., 2005; Visch et al., 1986; Vissink, Burlage,  
179 Spijkervet, Veerman, & Nieuw Amerongen, 2004). Four studies asked subjects to report on the  
180 improvement in dryness related to the use of saliva substitutes (Salom et al., 2015; Silvestre et  
181 al., 2009; Stewart et al., 1998; van der Reijden et al., 1996). Six studies reported the impact of  
182 xerostomia on Quality of life (GOHAI (McMillan et al., 2006), OHIP 14 (Gil-Montoya et al.,  
183 2008; Skrinjar et al., 2015), EORTC - QLQ + H&35 (Heydarirad et al., 2017; Jellema et al.,  
184 2001), QoL (Dirix et al., 2007)). In one observation report, the staff of an establishment for  
185 elderlies measured meal duration, reported the residents' pain complaints and subjectively  
186 assessed their ability to speak, eat and swallow (Blixt-Johansen et al., 1992). Sixteen studies  
187 globally measured the impact of xerostomia using validated (Apperley et al., 2017; Bots et al.,  
188 2005; McMillan et al., 2006; Morales-Bozo et al., 2017), or non validated (Alves et al., 2004;  
189 Andersson et al., 1995; Frost et al., 2002; Furumoto et al., 1998; Gil-Montoya et al., 2008;  
190 Klestov et al., 1981; Momm et al., 2005; Mouly, Orlor, et al., 2007; Mouly, Salom, et al., 2007;  
191 Oh et al., 2008; Shahdad et al., 2005; Sweeney et al., 1997) comprehensive questionnaires.

192 Xerostomia was described in different conditions of gender, age and medical condition. The  
193 age range was from 18 to 94 and gender was not a criterion for inclusion. The medical  
194 conditions observed were: radiotherapy and/or chemotherapy after head and neck cancers

195 (Andersson et al., 1995; Apperley et al., 2017; Dirix et al., 2007; Epstein & Stevenson-Moore,  
196 1992; Epstein et al., 1999; Jellema et al., 2001; Momm & Guttenberger, 2002; Nakamoto, 1979;  
197 Regelin et al., 1998; Shahdad et al., 2005), systemic auto immune disease (Aliko et al., 2012;  
198 Alpöz et al., 2008; Alves et al., 2004; Klestov et al., 1981; van der Reijden et al., 1996); drug  
199 consumption (Donath et al., 2016; Mouly, Orler, et al., 2007; Skrinjar et al., 2015); elderlies  
200 (Mouly, Salom, et al., 2007; Rogus-Pulia et al., 2018); final stage renal disease on  
201 haemodialysis (Bots et al., 2005). Regardless of the aetiology of xerostomia, controlling the  
202 effect of saliva substitutes on the production of a swallowable food bolus is of importance.

203 The possible effects of saliva substitutes on FOP were reported in 44 articles for swallowing  
204 only (Blixt-Johansen et al., 1992; Davies et al., 1998; Davies & Singer, 1994; Dirix et al., 2007;  
205 Donath et al., 2016; Epstein et al., 1999; Jellema et al., 2001; Klestov et al., 1981; Matear &  
206 Barbaro, 2005; Morales-Bozo et al., 2017; Nakamoto, 1979; Rogus-Pulia et al., 2018; van der  
207 Reijden et al., 1996) and in one article for mastication with objective measurements (Apperley  
208 et al., 2017). Evaluation of difficulties/easiness to swallow, to chew, to eat and/or to sip liquids  
209 were reported in 22 studies. Positive effects on FOP based on statistical analysis were assessed  
210 in 14 studies (Aliko et al., 2012; Alpöz et al., 2008; Alves et al., 2004; Andersson et al., 1995;  
211 Frost et al., 2002; Heydarirad et al., 2017; McMillan et al., 2006; Momm et al., 2005; Morales-  
212 Bozo et al., 2017; Mouly, Orler, et al., 2007; Mouly, Salom, et al., 2007; Rogus-Pulia et al.,  
213 2018; Salom et al., 2015; Shahdad et al., 2005). Only one clinical trial measured xerostomia  
214 with a validated questionnaire and compared the effects of three different saliva substitutes on  
215 the chewing kinematics during ingestion of crackers (Apperley et al., 2017). The Test ~~of~~ **Of**  
216 **Mastication and Swallowing Solids (TOMASS)** required ingestion of a cracker as quickly  
217 and as comfortably as possible (Hägglund, Blom, Thoden, & Karlsson, 2020; Huckabee et al.,  
218 2018). During mastication, the number of cycles, chewing time, and swallows per bite were  
219 measured. It was found that the use of saliva substitutes slightly improved xerostomia but had

Mis en forme : Anglais (États-Unis)

220 no effect on chewing kinematic parameters during the cracker eating. The authors suggested  
221 that TOMASS test was not appropriate to evaluate mastication in subjects with xerostomia.

222

#### 223 4 DISCUSSION

224 This review ~~demonstrated~~ showed that the possible effects of the use of saliva substitutes on  
225 the ingestion function were poorly investigated. No evidence ~~is~~ was based on physiological  
226 studies. Saliva participates in food bolus constitution, affects its rheological properties and  
227 initiates digestion. Food bolus rheology has a dominant influence on mastication and  
228 swallowing (Chen, 2007). During FOP, saliva gradually fills the gap between food particles and  
229 increases their viscous cohesion. The swallowing threshold is defined as the moment when the  
230 food bolus reaches the maximum cohesive force (Prinz & Lucas, 1997). It is unknown whether  
231 the use of a saliva substitute has an effect on the composition and the rheological properties of  
232 the food bolus, on the lubrication of the oral and laryngeal mucosa or on both these phenomena.  
233 Moreover, it is clear that saliva substitutes are not developed to improve FOP. For example,  
234 most of the saliva substitute listed in Table 1 have mint, grapefruit, lemon or sweet flavouring.  
235 A flavoured saliva substitute could affect the perception of food and could limit the use of the  
236 saliva substitute during meals. Spontaneous food consumption could be altered for individuals  
237 using a saliva substitute, independently of the consequences of xerostomia.

238 Natural saliva is a non-Newtonian fluid. This characteristic ensures bolus aggregation and the  
239 lubrication of the oral and laryngeal mucosa during FOP. It could be suggested that a saliva  
240 substitute should be a non-Newtonian fluid. However, among the saliva substitutes used within  
241 the 14 studies reporting a possible positive effect of saliva substitutes on FOP, seven were based  
242 on mucine and/or xanthan gum and could be considered as natural saliva simulators (NSS), six  
243 were Newtonian fluids based on carboxymethyl cellulose or glycerol and two were

244 uncategorized (Table 12). In most cases, non-Newtonian saliva substitutes contain substances  
245 of natural origin (salivary macromolecules such as mucins, lysozyme, lactoferrin) that provide  
246 high biocompatibility. However, mucines have pig or cow origins, which can affect the uses of  
247 the corresponding saliva substitute in some individuals for cultural reasons. The challenges of  
248 treating xerostomia are to mimic all properties of natural saliva definitely in order to improve  
249 oral comfort between and during meals.

250 The selection criteria of this review excluded the “saliva stimulant” keyword. Saliva stimulants  
251 are parasympathomimetics such as Pilocarpine or Cevimeline. These substances are indicated  
252 to improve the production of saliva compared with a placebo (LeVeque et al., 1993). The use of  
253 chewing gum was also described to increase saliva production. However, chewing a gum can  
254 be indicated only for persons whose salivary glands respond to stimulation. Saliva stimulant  
255 cannot meet the needs of all patients with xerostomia, contrary to saliva substitutes. It can be  
256 difficult to determine the amount of saliva that is indicative of the dysfunction of the salivary  
257 glands. The measurement of the salivary flow is the basis for the diagnosis of  
258 xerostomia/hyposalivation. Among the included studies, 28 reported a measure of saliva flow  
259 (Aliko et al., 2012; Alpöz et al., 2015, 2008; Andersson et al., 1995; Bots et al., 2005; Dalodom  
260 et al., 2016; Donath et al., 2016; Duxbury et al., 1989; Epstein et al., 1999; Epstein & Stevenson-  
261 Moore, 1992; Frost et al., 2002; Furumoto et al., 1998; McMillan et al., 2006; Morales-Bozo et  
262 al., 2017; Mouly, Orlor, et al., 2007; Mouly, Salom, et al., 2007; Oh et al., 2008; Regelink et  
263 al., 1998; Silvestre et al., 2009; Skrinjar et al., 2015; Stewart et al., 1998; Sweeney et al., 1997;  
264 van der Reijden et al., 1996). Overall, hyposalivation was observed when salivary flow rate at  
265 rest falls below 0.1 mL per minute and stimulated saliva (Sreebny, 2000) below 0.5–0.7 mL per  
266 minute; (Navazesh, Christensen, & Brightman, 1992; Ship, DeCarli, Friedland, & Baum, 1990).  
267 However, the sialometric techniques used to measure the salivary flow varied a lot, the spitting  
268 method being the most often reported. Moreover, the salivary flow rate threshold as an

269 inclusion/exclusion criterion was set at different levels in different studies. Overall, the saliva  
270 flow was measured in 22 studies, while only seven studies considered the value of the saliva  
271 flow as an inclusion criterion (Table 23).

272 To conclude, this review underscores the need to develop new saliva substitutes to improve the  
273 rheological properties of the bolus and the lubrication of the laryngeal mucosa. Flavours should  
274 be excluded from their composition.

275

## 276 **ETHICAL STATEMENT**

277

278 **Declarations of interest:** The authors declare that they do not have any conflict of interest  
279

280

281

## 281 **REFERENCES**

282 Aliko, A., Alushi, A., Tafaj, A., & Isufi, R. (2012). Evaluation of the clinical efficacy of Biotène

283 Oral Balance in patients with secondary Sjögren's syndrome: A pilot study.

284 *Rheumatology International*, 32(9), 2877–2881. <https://doi.org/10.1007/s00296-011->

285 2085-6

286 Alpöz, E., Çankaya, H., Güneri, P., Epstein, J. B., Boyacioglu, H., Kabasakal, Y., & Ocakci, P.

287 T. (2015). Impact of Buccotherm® on xerostomia: A single blind study. *Special Care*

288 *in Dentistry*, 35(1), 1–7. <https://doi.org/10.1111/scd.12074>

289 Alpöz, E., Güneri, P., Onder, G., Cankaya, H., Kabasakal, Y., & Köse, T. (2008). The efficacy

290 of Xialine in patients with Sjögren's syndrome: A single-blind, cross-over study.

291 *Clinical Oral Investigations*, 12(2), 165–172. <https://doi.org/10.1007/s00784-007->

292 0159-3

293 Alves, M. B., Motta, A. C. F., Messina, W. C., & Migliari, D. A. (2004). Saliva substitute in  
294 xerostomic patients with primary Sjögren's syndrome: A single-blind trial.  
295 *Quintessence International (Berlin, Germany: 1985)*, 35(5), 392–396.

296 Andersson, G., Johansson, G., Attström, R., Edwardsson, S., Glantz, P. O., & Larsson, K.  
297 (1995). Comparison of the effect of the linseed extract Salinum and a methyl cellulose  
298 preparation on the symptoms of dry mouth. *Gerodontology*, 12(1), 12–17.  
299 <https://doi.org/10.1111/j.1741-2358.1995.tb00124.x>

300 Apperley, O., Medlicott, N., Rich, A., Hanning, S., & Huckabee, M. L. (2017). A clinical trial  
301 of a novel emulsion for potential use as a saliva substitute in patients with radiation-  
302 induced xerostomia. *Journal of Oral Rehabilitation*, 44(11), 889–895.  
303 <https://doi.org/10.1111/joor.12545>

304 Blixt-Johansen, G., Sjöholm, K., Wiesel, K., & Ek, A. C. (1992). The condition of the oral  
305 mucosa in institutionalized elderly patients before and after using a mucin-containing  
306 saliva substitute. *Scandinavian Journal of Caring Sciences*, 6(3), 147–150.  
307 <https://doi.org/10.1111/j.1471-6712.1992.tb00142.x>

308 Bots, C. P., Brand, H. S., Veerman, E. C. I., Korevaar, J. C., Valentijn-Benz, M., Bezemer, P.  
309 D., ... Nieuw Amerongen, A. V. (2005). Chewing gum and a saliva substitute alleviate  
310 thirst and xerostomia in patients on haemodialysis. *Nephrology, Dialysis,*  
311 *Transplantation*, 20(3), 578–584. <https://doi.org/10.1093/ndt/gfh675>

312 Chen, J. (2007). Food oral processing—A review. *Food Hydrocolloids*, 23, 1–25.

313 Cuschieri, S. (2019). The STROBE guidelines. *Saudi Journal of Anaesthesia*, 13(Suppl 1),  
314 S31–S34. PubMed (30930717). [https://doi.org/10.4103/sja.SJA\\_543\\_18](https://doi.org/10.4103/sja.SJA_543_18)

315 Dalodom, S., Lam-Ubol, A., Jeanmaneechotechai, S., Takamfoo, L., Intachai, W., Duangchada,  
316 K., ... Trachootham, D. (2016). Influence of oral moisturizing jelly as a saliva substitute

317 for the relief of xerostomia in elderly patients with hypertension and diabetes mellitus.  
318 *Geriatric Nursing*, 37(2), 101–109. <https://doi.org/10.1016/j.gerinurse.2015.10.014>

319 Davies, A. N., Daniels, C., Pugh, R., & Sharma, K. (1998). A comparison of artificial saliva  
320 and pilocarpine in the management of xerostomia in patients with advanced cancer.  
321 *Palliative Medicine*, 12(2), 105–111. <https://doi.org/10.1191/026921698670435903>

322 Davies, A. N., & Singer, J. (1994). A comparison of artificial saliva and pilocarpine in radiation-  
323 induced xerostomia. *The Journal of Laryngology and Otology*, 108(8), 663–665.  
324 <https://doi.org/10.1017/s0022215100127768>

325 Dirix, P., Nuyts, S., Vander Poorten, V., Delaere, P., & Van den Bogaert, W. (2007). Efficacy  
326 of the BioXtra dry mouth care system in the treatment of radiotherapy-induced  
327 xerostomia. *Supportive Care in Cancer*, 15(12), 1429–1436.  
328 <https://doi.org/10.1007/s00520-006-0210-y>

329 Donath, F., Tonner, F., Chavda, R., Gatignol, J.-P., & Bouyrie, J. (2016). Randomized trial of  
330 the efficacy and safety of a new oral spray for drug-induced xerostomia. *Clinical and*  
331 *Experimental Dental Research*, 2(2), 112–120. <https://doi.org/10.1002/cre2.29>

332 Duxbury, A. J., Thakker, N. S., & Wastell, D. G. (1989). A double-blind cross-over trial of a  
333 mucin-containing artificial saliva. *British Dental Journal*, 166(4), 115–120.  
334 <https://doi.org/10.1038/sj.bdj.4806731>

335 Epstein, J., Emerton, S., Le, N. D., & Stevenson-Moore, P. (1999). A double-blind crossover  
336 trial of Oral Balance gel and Biotene® toothpaste versus placebo in patients with  
337 xerostomia following radiation therapy. *Oral Oncology*, 35(2), 132–137.  
338 [https://doi.org/10.1016/S1368-8375\(98\)00109-2](https://doi.org/10.1016/S1368-8375(98)00109-2)

339 Epstein, J., & Stevenson-Moore, P. (1992). A clinical comparative trial of saliva substitutes in  
340 radiation-induced salivary gland hypofunction. *Special Care in Dentistry*, 12(1), 21–23.  
341 <https://doi.org/10.1111/j.1754-4505.1992.tb00401.x>

342 Epstein, J., Thariat, J., Bensadoun, R.-J., Barasch, A., Murphy, B. A., Kolnick, L., ... Maghami,  
343 E. (2012). Oral complications of cancer and cancer therapy: From cancer treatment to  
344 survivorship. *CA: A Cancer Journal for Clinicians*, 62(6), 400–422.  
345 <https://doi.org/10.3322/caac.21157>

346 Fox, P. C., Busch, K. A., & Baum, B. J. (1987). Subjective reports of xerostomia and objective  
347 measures of salivary gland performance. *Journal of the American Dental Association*,  
348 115(4), 581–584. [https://doi.org/10.1016/s0002-8177\(87\)54012-0](https://doi.org/10.1016/s0002-8177(87)54012-0)

349 Frost, P. M., Shirlaw, P. J., Walter, J. D., & Challacombe, S. J. (2002). Patient preferences in a  
350 preliminary study comparing an intra-oral lubricating device with the usual dry mouth  
351 lubricating methods. *British Dental Journal*, 193(7), 403–408.  
352 <https://doi.org/10.1038/sj.bdj.4801576>

353 Furness, S., Bryan, G., McMillan, R., Birchenough, S., & Worthington, H. V. (2013).  
354 Interventions for the management of dry mouth: Non-pharmacological interventions.  
355 *The Cochrane Database of Systematic Reviews*, (9), CD009603.  
356 <https://doi.org/10.1002/14651858.CD009603.pub3>

357 Furness, S., Worthington, H. V., Bryan, G., Birchenough, S., & McMillan, R. (2011).  
358 Interventions for the management of dry mouth: Topical therapies. *The Cochrane*  
359 *Database of Systematic Reviews*, (12), CD008934.  
360 <https://doi.org/10.1002/14651858.CD008934.pub2>

361 Furumoto, E. K., Barker, G. J., Carter-Hanson, C., & Barker, B. F. (1998). Subjective and  
362 clinical evaluation of oral lubricants in xerostomic patients. *Special Care in Dentistry*,  
363 18(3), 113–118. <https://doi.org/10.1111/j.1754-4505.1998.tb00915.x>

364 Gil-Montoya, J. A., Subirá, C., Ramón, J. M., & González-Moles, M. A. (2008). Oral health-  
365 related quality of life and nutritional status. *Journal of Public Health Dentistry*, 68(2),  
366 88–93. <https://doi.org/10.1111/j.1752-7325.2007.00082.x>



367 Hägglund, P., Blom, S., Thoden, P., & Karlsson, F. (2020). The Test of Masticating and  
368 Swallowing Solids (TOMASS): Normative data for two crackers available in the  
369 Scandinavian and international markets. *International Journal of Speech-Language*  
370 *Pathology*, 1–9. <https://doi.org/10.1080/17549507.2020.1800090>

371 Hahnel, S., Behr, M., Handel, G., & Bürgers, R. (2009). Saliva substitutes for the treatment of  
372 radiation-induced xerostomia—A review. *Supportive Care in Cancer*, 17(11), 1331–  
373 1343. <https://doi.org/10.1007/s00520-009-0671-x>

374 Heydarirad, G., Rezaeizadeh, H., Choopani, R., Mosavat, S. H., & Ameri, A. (2017). Efficacy  
375 of a traditional Persian medicine preparation for radiation-induced xerostomia: A  
376 randomized, open-label, active-controlled trial. *Journal of Integrative Medicine*, 15(3),  
377 201–208. [https://doi.org/10.1016/S2095-4964\(17\)60333-9](https://doi.org/10.1016/S2095-4964(17)60333-9)

378 Hopcraft, M., & Tan, C. (2010). Xerostomia: An update for clinicians. *Australian Dental*  
379 *Journal*, 55(3), 238–244. <https://doi.org/10.1111/j.1834-7819.2010.01229.x>

380 Huckabee, M.-L., McIntosh, T., Fuller, L., Curry, M., Thomas, P., Walshe, M., ... Sella-Weiss,  
381 O. (2018). The Test of Masticating and Swallowing Solids (TOMASS): Reliability,  
382 validity and international normative data. *International Journal of Language &*  
383 *Communication Disorders*, 53(1), 144–156. <https://doi.org/10.1111/1460-6984.12332>

384 Iwasaki, M., Yoshihara, A., Ito, K., Sato, M., Minagawa, K., Muramatsu, K., ... Miyazaki, H.  
385 (2016). Hyposalivation and dietary nutrient intake among community-based older  
386 Japanese. *Geriatrics & Gerontology International*, 16(4), 500–507.  
387 <https://doi.org/10.1111/ggi.12500>

388 Jellema, A. P., Langendijk, H., Bergenhenegouwen, L., van der Reijden, W., Leemans, R.,  
389 Smeele, L., & Slotman, B. J. (2001). The efficacy of Xialine in patients with xerostomia  
390 resulting from radiotherapy for head and neck cancer: A pilot-study. *Radiotherapy and*  
391 *Oncology*, 59(2), 157–160. [https://doi.org/10.1016/s0167-8140\(01\)00336-x](https://doi.org/10.1016/s0167-8140(01)00336-x)

392 Johansson, G., Andersson, G., Attström, R., Glantz, P. O., & Larsson, K. (1994). The effect of  
393 Salinum on the symptoms of dry mouth: A pilot study. *Gerodontology*, *11*(1), 46–49.  
394 <https://doi.org/10.1111/j.1741-2358.1994.tb00102.x>

395 Klestov, A. C., Webb, J., Latt, D., Schiller, G., McNamara, K., Young, D. Y., ... Fetherston, J.  
396 (1981). Treatment of xerostomia: A double-blind trial in 108 patients with Sjögren's  
397 syndrome. *Oral Surgery, Oral Medicine, and Oral Pathology*, *51*(6), 594–599.  
398 [https://doi.org/10.1016/s0030-4220\(81\)80008-4](https://doi.org/10.1016/s0030-4220(81)80008-4)

399 Krop, E. M., Hetherington, M. M., Nekitsing, C., Miquel, S., Postelnicu, L., & Sarkar, A.  
400 (2018). Influence of oral processing on appetite and food intake—A systematic review  
401 and meta-analysis. *Appetite*, *125*, 253–269. <https://doi.org/10.1016/j.appet.2018.01.018>

402 LeVeque, F. G., Montgomery, M., Potter, D., Zimmer, M. B., Rieke, J. W., Steiger, B. W., ...  
403 Muscoplat, C. C. (1993). A multicenter, randomized, double-blind, placebo-controlled,  
404 dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in  
405 head and neck cancer patients. *Journal of Clinical Oncology*, *11*(6), 1124–1131.  
406 <https://doi.org/10.1200/JCO.1993.11.6.1124>

407 Liedberg, B., Ekberg, O., & Owall, B. (1991). Chewing and the dimension of the  
408 pharyngoesophageal segment. *Dysphagia*, *6*(4), 214–218.  
409 <https://doi.org/10.1007/bf02493530>

410 Longman, L. P., Higham, S. M., Bucknall, R., Kaye, S. B., Edgar, W. M., & Field, E. A. (1997).  
411 Signs and symptoms in patients with salivary gland hypofunction. *Postgraduate*  
412 *Medical Journal*, *73*(856), 93–97. <https://doi.org/10.1136/pgmj.73.856.93>

413 Łysik, D., Niemirowicz-Laskowska, K., Bucki, R., Tokajuk, G., & Mystkowska, J. (2019).  
414 Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia.  
415 *International Journal of Molecular Sciences*, *20*(13), 3199.  
416 <https://doi.org/10.3390/ijms20133199>

417 Matear, D. W., & Barbaro, J. (2005). Effectiveness of saliva substitute products in the treatment  
418 of dry mouth in the elderly: A pilot study. *The Journal of the Royal Society for the*  
419 *Promotion of Health*, 125(1), 35–41. <https://doi.org/10.1177/146642400512500113>

420 McMillan, A. S., Tsang, C. S. P., Wong, M. C. M., & Kam, A. Y. L. (2006). Efficacy of a novel  
421 lubricating system in the management of radiotherapy-related xerostomia. *Oral*  
422 *Oncology*, 42(8), 842–848. <https://doi.org/10.1016/j.oraloncology.2005.12.003>

423 Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., ... PRISMA-P  
424 Group. (2015). Preferred reporting items for systematic review and meta-analysis  
425 protocols (PRISMA-P) 2015 statement. *Systematic Reviews*, 4, 1.  
426 <https://doi.org/10.1186/2046-4053-4-1>

427 Momm, F., & Guttenberger, R. (2002). Treatment of xerostomia following radiotherapy: Does  
428 age matter? *Supportive Care in Cancer*, 10(6), 505–508.  
429 <https://doi.org/10.1007/s00520-002-0362-3>

430 Momm, F., Volegova-Neher, N. J., Schulte-Mönting, J., & Guttenberger, R. (2005). Different  
431 saliva substitutes for treatment of xerostomia following radiotherapy. A prospective  
432 crossover study. *Strahlentherapie Und Onkologie*, 181(4), 231–236.  
433 <https://doi.org/10.1007/s00066-005-1333-7>

434 Morales-Bozo, I., Ortega-Pinto, A., Rojas Alcayaga, G., Aitken Saavedra, J. P., Salinas Flores,  
435 O., Lefimil Puente, C., ... Urzúa Orellana, B. (2017). Evaluation of the effectiveness of  
436 a chamomile (*Matricaria chamomilla*) and linseed (*Linum usitatissimum*) saliva  
437 substitute in the relief of xerostomia in elders. *Gerodontology*, 34(1), 42–48.  
438 <https://doi.org/10.1111/ger.12220>

439 Mouly, S., Orler, J.-B., Tillet, Y., Coudert, A.-C., Oberli, F., Preshaw, P., & Bergmann, J.-F.  
440 (2007). Efficacy of a new oral lubricant solution in the management of psychotropic

441 drug-induced xerostomia: A randomized controlled trial. *Journal of Clinical*  
442 *Psychopharmacology*, 27(5), 437–443. <https://doi.org/10.1097/jcp.0b013e31814db434>

443 Mouly, S., Salom, M., Tillet, Y., Coudert, A.-C., Oberli, F., Preshaw, P. M., ... Bergmann, J.-  
444 F. (2007). Management of xerostomia in older patients: A randomised controlled trial  
445 evaluating the efficacy of a new oral lubricant solution. *Drugs & Aging*, 24(11), 957–  
446 965. <https://doi.org/10.2165/00002512-200724110-00007>

447 Nakamoto, R. Y. (1979). Use of a saliva substitute in postradiation xerostomia. *The Journal of*  
448 *Prosthetic Dentistry*, 42(5), 539–542. [https://doi.org/10.1016/0022-3913\(79\)90249-x](https://doi.org/10.1016/0022-3913(79)90249-x)

449 Navazesh, M., Christensen, C., & Brightman, V. (1992). Clinical criteria for the diagnosis of  
450 salivary gland hypofunction. *Journal of Dental Research*, 71(7), 1363–1369.  
451 <https://doi.org/10.1177/00220345920710070301>

452 Oh, D. J., Lee, J. Y., Kim, Y. K., & Kho, H. S. (2008). Effects of carboxymethylcellulose  
453 (CMC)-based artificial saliva in patients with xerostomia. *International Journal of Oral*  
454 *and Maxillofacial Surgery*, 37(11), 1027–1031.  
455 <https://doi.org/10.1016/j.ijom.2008.06.006>

456 Porter, S. R., Scully, C., & Hegarty, A. M. (2004). An update of the etiology and management  
457 of xerostomia. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and*  
458 *Endodontics*, 97(1), 28–46. <https://doi.org/10.1016/j.tripleo.2003.07.010>

459 Prinz, J. F., & Lucas, P. W. (1997). An optimization model for mastication and swallowing in  
460 mammals. *Proceedings. Biological Sciences*, 264(1389), 1715–1721.  
461 <https://doi.org/10.1098/rspb.1997.0238>

462 Regelink, G., Vissink, A., Reintsema, H., & Nauta, J. M. (1998). Efficacy of a synthetic  
463 polymer saliva substitute in reducing oral complaints of patients suffering from  
464 irradiation-induced xerostomia. *Quintessence International*, 29(6), 383–388.

465 Rogus-Pulia, N. M., Gangnon, R., Kind, A., Connor, N. P., & Asthana, S. (2018). A Pilot Study  
466 of Perceived Mouth Dryness, Perceived Swallowing Effort, and Saliva Substitute  
467 Effects in Healthy Adults Across the Age Range. *Dysphagia*, 33(2), 200–205.  
468 <https://doi.org/10.1007/s00455-017-9846-7>

469 Salom, M., Hachulla, E., Bertolus, C., Deschaumes, C., Simoneau, G., & Mouly, S. (2015).  
470 Efficacy and safety of a new oral saliva equivalent in the management of xerostomia: A  
471 national, multicenter, randomized study. *Oral Surgery, Oral Medicine, Oral Pathology*  
472 *and Oral Radiology*, 119(3), 301–309. <https://doi.org/10.1016/j.oooo.2014.12.005>

473 Shahdad, S. A., Taylor, C., Barclay, S. C., Steen, I. N., & Preshaw, P. M. (2005). A double-  
474 blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary  
475 substitutes in patients with post-radiotherapy xerostomia. *European Journal of Cancer*  
476 *Care*, 14(4), 319–326. <https://doi.org/10.1111/j.1365-2354.2005.00587.x>

477 Ship, J. A., DeCarli, C., Friedland, R. P., & Baum, B. J. (1990). Diminished submandibular  
478 salivary flow in dementia of the Alzheimer type. *Journal of Gerontology*, 45(2), M61-  
479 66.

480 Silvestre, F. J., Minguez, M. P., & Suñe-Negre, J. M. (2009). Clinical evaluation of a new  
481 artificial saliva in spray form for patients with dry mouth. *Medicina Oral, Patologia*  
482 *Oral Y Cirugia Bucal*, 14(1), E8–E11.

483 Skrinjar, I., Vucicevic Boras, V., Bakale, I., Andabak Rogulj, A., Brailo, V., Vidovic Juras, D.,  
484 ... Vrdoljak, D. V. (2015). Comparison between three different saliva substitutes in  
485 patients with hyposalivation. *Clinical Oral Investigations*, 19(3), 753–757.  
486 <https://doi.org/10.1007/s00784-015-1405-8>

487 Sreebny, L. M. (2000). Saliva in health and disease: An appraisal and update. *International*  
488 *Dental Journal*, 50(3), 140–161. <https://doi.org/10.1111/j.1875-595x.2000.tb00554.x>

489 Stewart, C. M., Jones, A. C., Bates, R. E., Sandow, P., Pink, F., & Stillwell, J. (1998).  
490 Comparison between saliva stimulants and a saliva substitute in patients with  
491 xerostomia and hyposalivation. *Special Care in Dentistry*, 18(4), 142–148.  
492 <https://doi.org/10.1111/j.1754-4505.1998.tb01136.x>

493 Sweeney, M. P., Bagg, J., Baxter, W. P., & Aitchison, T. C. (1997). Clinical trial of a mucin-  
494 containing oral spray for treatment of xerostomia in hospice patients. *Palliative*  
495 *Medicine*, 11(3), 225–232. <https://doi.org/10.1177/026921639701100307>

496 Temmel, A. F. P., Quint, C., Schickinger-Fischer, B., & Hummel, T. (2005). Taste function in  
497 xerostomia before and after treatment with a saliva substitute containing  
498 carboxymethylcellulose. *The Journal of Otolaryngology*, 34(2), 116–120.  
499 <https://doi.org/10.2310/7070.2005.04008>

500 van der Reijden, W. A., van der Kwaak, H., Vissink, A., Veerman, E. C., & Amerongen, A. V.  
501 (1996). Treatment of xerostomia with polymer-based saliva substitutes in patients with  
502 Sjögren's syndrome. *Arthritis and Rheumatism*, 39(1), 57–63.  
503 <https://doi.org/10.1002/art.1780390108>

504 Visch, L. L., Gravenmade, E. J., Schaub, R. M., Van Putten, W. L., & Vissink, A. (1986). A  
505 double-blind crossover trial of CMC- and mucin-containing saliva substitutes.  
506 *International Journal of Oral and Maxillofacial Surgery*, 15(4), 395–400.  
507 [https://doi.org/10.1016/s0300-9785\(86\)80027-8](https://doi.org/10.1016/s0300-9785(86)80027-8)

508 Vissink, A., Burlage, F. R., Spijkervet, F. K., Veerman, E. C. I., & Nieuw Amerongen, A. V.  
509 (2004). Prevention and treatment of salivary gland hypofunction related to head and  
510 neck radiation therapy and chemotherapy. *Supportive Cancer Therapy*, 1(2), 111–118.  
511 <https://doi.org/10.3816/SCT.2004.n.004>

512 Vissink, A., s-Gravenmade, E. J., Panders, A. K., Vermey, A., Petersen, J. K., Visch, L. L., &  
513 Schaub, R. M. (1983). A clinical comparison between commercially available mucin-

514 and CMC-containing saliva substitutes. *International Journal of Oral Surgery*, 12(4),  
515 232–238. [https://doi.org/10.1016/s0300-9785\(83\)80048-9](https://doi.org/10.1016/s0300-9785(83)80048-9)

516 Ying Joanna, N. D., & Thomson, W. M. (2015). Dry mouth—An overview. *Singapore Dental*  
517 *Journal*, 36, 12–17. <https://doi.org/10.1016/j.sdj.2014.12.001>

518

519

520 **Table 1: Aetiologies for xerostomia and criteria for evaluation of FOP functions in included**  
 521 **studies**

522

Studies	Xerostomia aetiology	FOP function targeted	Objectives measures	Subjectives measures
(Aliko et al., 2012)	Sjögren's Syndrome	Mastication Swallowing Taste	Salivary flow Quantity of SS' use	VAS
(Alpöz et al., 2008)	Sjögren's Syndrome	Taste Mastication Siping Speech Swallowing	Salivary flow	VAS
(Alpöz et al., 2015)	Mixed, unspecified	Chewing Sipping Swallowing Taste	Salivary flow Oral examination	Questionnaire
(Alves et al., 2004)	Sjögren's syndrome	Mastication Swallowing	Salivary flow	Questionnaire
(Andersson et al., 1995)	Radiotherapy	Chewing Swallowing Taste	Oral examination Salivary flow	Questionnaire
(Apperley et al., 2017)	Radiotherapy	Mastication Swallowing	Chewing cycles Chewing time Swallows/bite (TOMASS)	Questionnaire
(Blixt-Johansen et al., 1992)	Drugs Other unspecified	Eating Swallowing	Oral examination	Reports of frequency by Staff
(Bots et al., 2005)	Kidney failure	ND	Salivary flow	Questionnaire
(Dalodom et al., 2016)	Mellitous diabetes Hypertension	Chewing Swallowing Taste disturbance	Oral examination Salivary flow	VAS
(Davies & Singer, 1994)	Radiotherapy	Dysphagia Dysgeusia	ND	Questionnaire VAS
(Davies et al., 1998)	Cancer	Dysphagia Dysgeusia	ND	Questionnaire VAS
(Dirix et al., 2007)	Radiotherapy	Swallowing Taste	ND	Questionnaire VAS
(Donath et al., 2016)	Drugs	Swallowing	Oral examination Salivary flow	VAS
(Duxbury et al., 1989)	Drugs Diabetes Radiotherapy Sjögren's syndrome Smoking	Eating Taste	Frequency of SS' use Salivary flow	VAS
(Epstein & Stevenson-Moore, 1992)	Radiotherapy	ND	Frequency of SS' use Salivary flow	Questionnaire
(Epstein et al., 1999)	Radiotherapy	Swallowing Taste	Salivary flow	VAS
(Frost et al., 2002)	Buccal respiration Drugs Sjögren's syndrome Other	Chewing Swallowing	Oral examination Salivary flow	Questionnaire
(Furumoto et al., 1998)	Mixed, unspecified	Eating	Salivary flow	Questionnaire



		Swallowing		
(Gil-Montoya et al., 2008)	Aging	Biting Chewing Eating Swallowing	ND	Questionnaire
(Heydarirad et al., 2017)	Radiotherapy	Eating Swallowing Taste	ND	Questionnaire
(Jellema et al., 2001)	Radiotherapy	Swallowing	Frequency of SS' use	Questionnaires
(Johansson et al., 1994)	Drugs Radiotherapy Sjögren's Syndrome	Mastication Swallowing Taste	Oral examination	Questionnaire
(Klestov et al., 1981)	Sjogren's syndrome	Chewing Drinking Swallowing	ND	Questionnaire
(Matear & Barbaro, 2005)	Aging Drugs Systemic diseases	Swallowing	ND	Questionnaire
(McMillan et al., 2006)	Radiotherapy	Biting Chewing Eating Swallowing	Salivary flow	Questionnaire
(Momm et al., 2005)	Radiotherapy	Chewing Eating Swallowing	ND	Questionnaire
(Morales-Bozo et al., 2017)	Various	Swallowing	Salivary flow	VAS
(Mouly, Orlor, et al., 2007)	Aging	Chewing Swallowing Taste	Oral examination Salivary flow	VAS
(Mouly, Salom, et al., 2007)	Drugs	Chewing Swallowing Taste	Frequency of SS' use Oral examination Salivary flow	Questionnaire VAS
(Nakamoto, 1979)	Radiotherapy	Eating Swallowing Taste	ND	Questionnaire
(Oh et al., 2008)	Sjögren's syndrome Autoimmune disorders Radiotherapy	Chewing Eating Sipping Swallowing	Salivary flow	Questionnaire
(Regelink et al., 1998)	Radiotherapy		Salivary flow	Questionnaire
(Rogus-Pulia et al., 2018)	Aging	Swallowing	ND	One single question
(Salom et al., 2015)	Autoimmune disorders Drugs Radiotherapy Sjögren's syndrome Other various medical conditions	Chewing Swallowing Taste	ND	Questionnaire VAS
(Shahdad et al., 2005)	Radiotherapy	Chewing Swallowing Taste	ND	Questionnaire VAS
(Silvestre et al., 2009)	Drugs Radiotherapy	Eating Swallowing	Frequency of SS' use Salivary flow	VAS
(Skrinjar et al., 2015)	Drugs	Taste Mastication	Salivary flow	Questionnaire VAS

(Stewart et al., 1998)	Auto-immune disease Drugs Radiotherapy	Eating Sipping Swallowing Taste	Salivary flow	Questionnaire VAS
(Sweeney et al., 1997)	Motor neurone disease cancer	Eating Taste	Salivary flow	VAS
(Temmel et al., 2005)	Sjögren's syndrome Menopause	Taste	Frequency of SS' use Oral examination	Questionnaire
(van der Reijden et al., 1996)	Sjögren's syndrome Autoimmune disorders	Eating Swallowing Taste	Salivary flow	Questionnaire
(Visch et al., 1986)	Radiotherapy Sjögren's syndrome	Chewing Swallowing	ND	Questionnaire
(Vissink et al., 1983)	Drugs Radiotherapy Sjögren's syndrome Other unspecified	Mastication Swallowing Taste	Oral examination Salivary presence	Questionnaire

523

524

525

Table 2 Composition of saliva substitute used in the included studies (NSS: Natural saliva simulators: saliva substitutes containing mucin or mucin with xanthan or guar gum

Name	Composition	NSS	Form	Aromas	Instructions for use	Placebo or Control	References
<b>Aequasyl®</b>	94.4% triesters of glycerol; Oxidized fatty acids of vegetal origin (corn oil) Silicium dioxide Aspartame	No	Spray	Orange, Grapefruit, And mint Aspartam	2 spray (one by cheek then swill the product with the tongue until it had coated oral mucosa, after breakfast, and 15 min before a standard meal		(Donath et al., 2016)
					At least 5 times/day		(Mouly, Orlor, et al., 2007)
					1 or 2 spray up to 4 times a day		(Mouly, Salom, et al., 2007)
<b>Novasial®</b>			Sticks		One stick 4 times a day	<b>Aequasyl®</b> <b>Biotène®</b>	(Salom et al., 2015)
			Spray		One spray four times a week		
<b>DC161- DP0293</b>	Paraffin liquid, Cotton refine oil, Alphanatocopheryle acetate (oily solution)	No	Spray	Orange flavor	3 sprays (one by cheek, one on the tongue,) twice a day. One after breakfast, and one 15 min before a standard meal		(Donath et al., 2016)
<b>DC161- DP0291</b>	Glycerol, Polysorbate 80, Soja lecithin, Sodium hyaluronate, Xanthan gum, Potassium chloride, Xylitol, Anhydrous disodiumhydrogen phosphate, potassium dihydrogen, phosphate, sucralose, macrogolglycerol 40 hydroxystearate, benzylic, alcohol, Sodium benzoate, Cetylpyridinium chloride, alpha, tocopheryle	Yes	Spray	soft mint flavor	3 sprays (one by cheek, one on the tongue,) twice a day. One after breakfast, and one 15 min before a standard meal		(Donath et al., 2016)

	acetate, Water. (Aqueous solution)						
<b>DC161-DP0292</b>	Glycerol, Povidone K30, Copovidone, xanthan Gum, Potassium chloride, Xylitol, Marshmallow concentrated hydroglycerined extract, Anhydrous disodium hydrogen phosphate, potassium dihydrogen phosphate, Macrogolglycerol 40 hydroxystearate, Potassium sorbate, benzylic alcohol, Water	Yes	Spray		3 sprays (one by cheek, one on the tongue,) twice a day. One after breakfast, and one 15 min before a standard meal		(Donath et al., 2016)
<b>Biotene Oral Balance®</b>	Lactoperoxidase, Lysozyme Glucose oxidase, Lactoferrin, Hydrogenated starch, Polymethacrylate, Xylitol sweetening; Hydroxyethyl sweetening Cellulose, Potassium thiocyanate, Aloe vera.	No	Gel	Sweetening	1 cm of gel on tongue and oral mucosa		(Aliko et al., 2012; Frost et al., 2002; Regelink et al., 1998; Rogus-Pulia et al., 2018; Shahdad et al., 2005)
						Carboxymethylen : 0.8% Triethanolamine Xylitol Nipagim : 0.3%	(Alves et al., 2004)
<b>Biotene mouthwash® and Oral Balance gel®</b>	Lactoperoxidase, Lysozyme, Glucose oxidase, Lactoferrin		Mouthwash	Slightly mentholed flavour and xylitol sweetening	Three times a day after brushing the teeth and/or dentures (12 ml) during 30 seconds	Aqueous solution with mint essence	(Gil-Montoya et al., 2008)
			Gel		Following the mouthrinse, 1 cm of gel on tongue and oral mucosa	Cream of similar appearance and flavor was prepared using carboxymethyl cellulose	

<b>Oral Balance gel and Biotene toothpaste®</b>		No	Gel Toothpaste			CMC gel and commercial toothpaste	(Epstein et al., 1999)
<b>Oral Balance gel and Biotene toothpaste and Mouthwash®</b>		No	Gel Toothpaste Mouthwash				(Matear & Barbaro, 2005; Shahdad et al., 2005)
<b>Device and Oral Balance gel</b>		No	Gel		At night		(Frost et al., 2002)
					Gel alone in the form of an oral bolus Gel on demand via an intra-oral device(at least 4hours per day and remove it at night)		(McMillan et al., 2006)
<b>Xialine®</b>	Polysaccharide xanthan gum, sodium fluoride	Yes	Spray	Mint-taste	At least 6 times a day	Water Dilued tea	(Alpöz et al., 2008)
				Mint-taste	At least 6 times/ day		(Bots et al., 2005)
				Neutral taste	At least 4 times a day	Xialine without Xanthan gum	(Jellema et al., 2001)
<b>Xanthan gum high viscosity</b>	KCl,NaCl,MgCl <sub>2</sub> ,CaCl <sub>2</sub> , Methylhydroxybenzoate, Benzalkonium chloride, Keltrol KTL, Distilled water	Yes		Peppermint flavour			(van der Reijden et al., 1996)
<b>Xanthan gum low viscosity</b>	KCl,NaCl,MgCl <sub>2</sub> ,CaCl <sub>2</sub> , Methylhydroxybenzoate, Benzalkonium chlorid, Keltrol KTL, Distilled water	Yes		Peppermint flavour			(van der Reijden et al., 1996)
<b>Polyacrylic acide</b>	KCl,NaCl,MgCl <sub>2</sub> ,CaCl <sub>2</sub> , Methylhydroxybenzoate, Benzalkonium chloride, Carbopol, Distilled water	No		Peppermint flavour			(van der Reijden et al., 1996)
<b>Saliva Orthana®</b>	Mucin, xylitol, Potassium chloride, sodium chloride,	Yes	Mouthwash	Neutral-tasting	Rince + swallow with 5ml 3 times/day before meal		(Blixt-Johansen et al., 1992)

	magnésium, calcium, dipotassium hydrogenophosphate, Methagine, Benzalconchloride, Sodium-EDTA			Peppermint flavor	Ad libitum	KCl, NaCl, MgCl <sub>2</sub> , CaCl <sub>2</sub> , methylhydroxybenzoate, benzalkonium chloride, distilled water	(van der Reijden et al., 1996)
				Peppermint flavor	Ad libitum		(Visch et al., 1986)
					Ad libitum		(Vissink et al., 1983)
			Spray	Peppermint flavor	2-3 sprays when required	Saliva Orthana® its no-mucin base Flavored distilled water	(Duxbury et al., 1989)
							(Davies et al., 1998; Davies & Singer, 1994; Sweeney et al., 1997)
					At least twice per day	Saliva Orthana® its no-mucin base	
<b>BioXtra®</b>	Hydroxyethylcellulose, Polyglyceryl methacrylate, Lactoperoxidase, Glucose oxidase, Lactoferrin, lysozyme and Monofluorophosphate and Xylitol (=oralbalance gel)+ peptides and Immunoglobulins	No	System: toothpaste mouthwash gel	Sweetening (less than OB)	Apply to your tongue and gums with your fingertip or a cotton swab Ad libitum		(Dirix et al., 2007; Shahdad et al., 2005)
<b>HCC Spray</b>		No	spray		Ad libitum		(Furumoto et al., 1998)
<b>Hydroxyethylcellulose citric acid spray</b>							
<b>Hydroxyethylcellulose gel</b>		No	gel		Ad libitum		
<b>Salinum®</b>	Linseed mucilage: 54% Protein: 9%		Mouthwash		Dosage of 2 ml of fluid Ad libitum		(Andersson et al., 1995; Johansson et al., 1994)

<b>Plant mucilage</b>	Matricaria chamomilla Linseed (linum usitatissimum)		Mouthwash		2ml 4 times a day		(Morales-Bozo et al., 2017)
<b>Carboxyméthyl Cellulose (Original preparations: CMC, MAS-84, CMC-NZ, CMC Spray)</b>	Sodium carboxymethylcellulose	No		Peppermint flavor	Plastic bottle 2 ml portion		(Andersson et al., 1995; Apperley et al., 2017)
					2ml 4 times a day		(Morales-Bozo et al., 2017; Temmel et al., 2005)
					Ad libitum		(Visch et al., 1986)
					Ad libitum		(Furumoto et al., 1998)
					Ad libitum		(Vissink et al., 1983)
					2ml Ad libitum		(Oh et al., 2008)
<b>VA-Oralube®</b>	Carboxymethylcellulose Water Sorbitol Preservative Fluorure, Ions Dry concentrate	No	Squeeze bottle		Ad libitum		(Epstein & Stevenson-Moore, 1992)
				Peppermint flavor	Ad libitum		(Vissink et al., 1983)
				Peppermint flavor	Ad libitum		(Nakamoto, 1979)
<b>Salivart</b>	Carboxymethylcellulose	No	Spray		Ad libitum		(Epstein & Stevenson-Moore, 1992)
<b>Moistir</b>	Carboxymethylcellulose	No	Spray		Ad libitum		(Epstein & Stevenson-Moore, 1992)
<b>Polyox</b>	Polyethylene oxide 1% Water		Glassbottle	Tasteless	Ad libitum		(Epstein & Stevenson-Moore, 1992)
<b>New oily formulation</b>	Rice bran oil (RBO Alfa One®) : 30% w/w	No	Spray	Flavoring	At least 4 times a day	Distilled water	(Apperley et al., 2017)

	Soy lecithin 30% w/w Propylene glycol Water: 40% w/w						
<b>OMJ® (Oral Moisturizing Jelly)</b>	Water-releasing (jelly)		Gel	Strawberry flavour or lime mint flavour	10 ml (spoon) 5 times/ day		(Dalodom et al., 2016)
<b>New preparation saliva substitute</b>	Distilled water Methylcellulose Spirit of chloroform KCl, NaF, CaCl.		Mouthwash 5ml	Essence of lemon	Ad libitum	Glycerine mouthwash Distilled water Spirit of chloroform	(Klestov et al., 1981)
<b>Aldiamed® gel</b>	Aloe vera gel				Ad libitum		(Momm et al., 2005)
<b>Glandosane® spray</b>	Carboxymethylcellulose	No			Ad libitum		(Momm et al., 2005)
<b>Rape spray</b>	Rape oil pressed		Spray		Ad libitum		(Momm et al., 2005)
<b>Margarine</b>	Liquid margarine				Ad libitum		(Furumoto et al., 1998)
<b>Saliva Medac® spray</b>	containing mucin extracted from pig stomach	Yes	Spray		Ad libitum		(Momm et al., 2005)
<b>Salivèze®</b>	aqueous electrolyte-containing solution calcium chloride 0.15 mg/mL, magnesium chloride 0.05 mg/mL, sodium chloride 0.05 mg/mL, potassium chloride 1.2 mg/ML, sodium phosphate 0.28 mg/mL and sorbitol 30 mg/mL in purified water		Spray		At least 5 times/day 1 or 2 spray up to 4 times a day		(Mouly, Orlor, et al., 2007; Mouly, Salom, et al., 2007)
<b>New artificial saliva formulation</b>	aqueous solution of potassium thiocyanate, potassium chloride, sodium chloride, calcium chloride, magnesium chloride, potassium dihydrogen phosphate, xylitol and citric acide		Spray	Flavor	At least 2 times / day		(Silvestre et al., 2009)



<b>Buccotherm®</b>	Thermal spring water		Spray		4 times daily		(Skrinjar et al., 2015)
					6 times daily	1/10 diluted black tea (plain water and Lipton tea)	(Alpöz et al., 2015)
<b>Xeros®</b>	Betaine, Sodium fluoride, Hydroxyethylcellulose	No	Mouthwash		4 times daily		(Skrinjar et al., 2015)
<b>Marshmallow root</b>	Infusion of marshmallow root into 2 dcl of cold water		Mouthwash		Rinsing with one large spoon 4 h after preparation		(Skrinjar et al., 2015)
<b>Mouth-Kote®</b>	Yerba santa (Eriodictyon californicum), Xylitol		Spray	Lemon flavor (sorbitol/xylitol-sweetened)	Ad libitum		(Stewart et al., 1998)
<b>TPM (Traditional Persian Medicine)</b>	Sachet 4 g of mixed powder of <i>A. digitata</i> and <i>M. Sylvestris</i> (in a proportion of 1:1), in a glass of boiled water (250 mL) as one dose. After 10 min, when the herbal infusion somewhat cooled, the patients were to sip the entire		Sip/Drink				(Heydarirad et al., 2017)
			Spray			HypoZalix spray (sodium carboxymethyl cellulose)	

Code de champ modifié

Table 3: Values of saliva flow rate in the set of seven studies considering saliva flow rate as inclusion criteria

<b>REFERENCES</b>	<b>Unstimulated saliva method</b>	<b>flow rate</b>
(Alpöz et al., 2008)	Spitting method 5 min	<0.3mL/min
(Andersson et al., 1995)	Spitting method 15 min	<1.5mL
(Donath et al., 2016)	Swab/test of saliva weight absorbed 5 min	≤0.5g
(Furumoto et al., 1998)	Spitting method 5 min	<0.2 mL/min
(Mouly, Orler, et al., 2007; Mouly, Salom, et al., 2007)	Swab/test of saliva weight absorbed 5 min	≤0.5g
	Spitting method	≤0.16 mL/min
	<b>Stimulated saliva method</b>	<b>flow rate</b>
(Alpöz et al., 2008)	Drops of acid citric spitting method	<1mL/min
(Alves et al., 2004)	Acid citric on cotton swab 5 min test spitting	<0.5mL/min
(Andersson et al., 1995)	Paraffin chewing 5 min	<3.5mL
(Gil-Montoya et al., 2008)	Chewing paraffin 5 min	≤0.7mL/min
(Mouly, Orler, et al., 2007; Mouly, Salom, et al., 2007)	Chewing paraffin Spitting method	≤0.5mL/min